GNS561
Primary Liver Cancers (e.g., Hepatocellular Carcinoma)
Phase 2Active (Licensed to Genfit)
Key Facts
Indication
Primary Liver Cancers (e.g., Hepatocellular Carcinoma)
Phase
Phase 2
Status
Active (Licensed to Genfit)
Company
About Genoscience Pharma
Genoscience Pharma is a private, clinical-stage biotech innovating in oncology and fibrotic diseases by targeting lysosomal biology. Its lead asset, GNS561, is in clinical development for primary liver cancers, and the company has secured European funding for a program in idiopathic pulmonary fibrosis (IPF). The company leverages a novel scientific platform and has established key partnerships, such as an exclusive licensing deal with Genfit for GNS561 in oncology, to advance its pipeline.
View full company profile